



VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001 (03.12.01)
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES

Cambridge, Massachusetts
April 12, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence Branch

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

This is in response to the Notice To File Corrected Application Papers - Filing Date Granted, mailed February 14, 2002 ("the Notice"). The Notice indicates that the application is informal as filed and the following items are required:

- (a) substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52; and
- (b) a Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825.

Applicants submit herewith the required Sequence Listing and statement pursuant to 37 C.F.R. §§ 1.821-1.825. Applicants also submit a Preliminary

Amendment, filed concurrently herewith, directing the entry of the Sequence Listing into the application.

Applicants also submit herewith substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52. The substitute specification contains no new matter.

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Andrea L.C. Robidoux
(Reg.No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483